Inovio Pharmaceuticals Inc vs Main Street Capital Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while Main Street Capital Corporation trades at $59 (market cap $5.52B). The key difference: Main Street Capital Corporation is far larger — about 70.3× Inovio Pharmaceuticals Inc's market cap, and Main Street Capital Corporation pays a 5.39% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MAIN | |
|---|---|---|
Market Cap | $78.55M | $5.52B |
Sector | Health | Financials |
52-Week High | $2.87 | $67.54 |
52-Week Low | $0.66 | $49.63 |
Enterprise Value | $49.56M | — |
Dividend Yield | — | 5.39% |
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →